Complexity of intermittent letrozole adjuvant therapy
Mené sur 4 884 patientes atteintes d'un cancer du sein après la ménopause, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, d'un traitement adjuvant à base de létrozole dispensé de façon continue et dispensé de façon intermittente (durée médiane de suivi : 60 mois)
To improve the outcomes of postmenopausal women with early-stage breast cancer is an important ongoing research goal. In The Lancet Oncology, Marco Colleoni and colleagues1 of the International Breast Cancer Study Group attempted to address this important research question in the Study Of Letrozole Extension (SOLE) trial in which they evaluate a novel approach to aromatase inhibitor administration—namely, extended intermittent use of adjuvant letrozole. At 5 years' follow-up, they report that disease-free survival did not differ significantly between women who received extended intermittent letrozole and those given continuous letrozole (hazard ratio 1·08, 95% CI 0·93–1·26; p=0·31).
The Lancet Oncology , commentaire, 2016